Harmony Biosciences (HRMY) stock skips as the company's treatment for the neurobehavioral condition Fragile X syndrome fails in a late-stage trial. Read more here.
Harmony Bio posts trial setback for Fragile X therapy (HRMY)
Harmony Biosciences (HRMY) stock skips as the company's treatment for the neurobehavioral condition Fragile X syndrome fails in a late-stage trial. Read more here.